The relationship between bladder wall thickness and lower urinary tract symptoms: Does bladder wall thickness change after alpha-blocker therapy with alfuzosin?

Abstract

Cite as: Can Urol Assoc J 2014;8(1-2):e26-9. http://dx.doi.org/10.5489/cuaj.1513 Published online January 14, 2014. AbstractIntroduction: We evaluate the association between lower urinary tract symptoms (LUTS) and bladder wall thickness (BWT) and investigate whether alfuzosin might improve BWT. Methods: We retrospectively reviewed the data of 164 patients with LUTS. Patients were divided into 2 groups according to BWT (Group 1: BWT ≤5 mm, n = 69; Group 2: BWT >5 mm, n = 95). Age, international prostate symptom score (IPSS), maximum and average urinary flow rates (Qmax and Qave), quality of life (QoL), postvoid residual (PVR) urine volume, prostate volume and prostate-specific antigen (PSA) were compared between the 2 groups. In total, 102 patients underwent transurethral resection of the prostate (TURP) and 62 patients were treated with alfuzosin. We compared BWT, Qmax, Qave, IPSS, QoL, PVR and PSA before and at the sixth month of alfuzosin therapy. A p value of <0.05 was considered statistically significant.

Establishment and value assessment of efficacy prediction model about transurethral prostatectomy

“…BWT has been shown to improve with alpha‐blocker therapy, and negatively correlate with the responsiveness of alpha‐blockers. Similar to BWT, DWT has been found to correlate with BOOI and decrease in DWT after transurethral prostatectomy …”

Bladder wall thickness in women with symptoms of overactive bladder and detrusor overactivity: Results from the randomised, placebo-controlled shrink study

“…Results for the >5 mm group are consistent with those from a similar study with tolterodine, where a significant BWT reduction was observed after 12 weeks versus placebo in patients with baseline BWT of >5 mm; however, no patients with BWT ≤5 mm were included in this study for comparison. Recent retrospective evaluation of BWT in men with LUTS included baseline BWT above and below 5 mm, and found BWT reductions from 6.8 to 4.6 mm in a patient subgroup treated with alfuzosin for 12 weeks. It remains unclear whether this result reflects a true effect of treatment on BWT in men, since only patients with baseline BWT >5 mm were treated with alfuzosin and included in this analysis, based on the pre‐treatment baseline BWT value of 6.8 mm.…”

Dutasteride add‐on therapy reduces detrusor mass in patients with benign prostatic enlargement not satisfied with alpha‐adrenergic antagonist monotherapy: A single center prospective study

“…Franco et al, moreover, noted a highly significant correlation between IPP and BOO and highlighted that the association of this parameter with BWT produced the best diagnostic accuracy . Some authors, furthermore, depicted BWT as a good predictor of the outcomes after medical/surgical treatment of LUTS/BPH …”